Reaction
Hyperplasia reporting signals
As of the last recalculation, Hyperplasia appears in 893 FAERS reports alongside 14 co-occurring drug terms. The strongest observed disproportionality signal is BASILIXIMAB (PRR 30.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Basiliximab | 15 | 30.2 | 30.3 |
| Canakinumab | 13 | 28.4 | 28.4 |
| Ganciclovir | 12 | 27.7 | 27.7 |
| Ganciclovir Sodium | 12 | 26.8 | 26.8 |
| Busulfan | 17 | 25.7 | 25.7 |
| Quinine | 8 | 21.9 | 21.9 |
| Anakinra | 15 | 21.4 | 21.4 |
| Gefitinib | 8 | 20.8 | 20.9 |
| Valganciclovir Hydrochloride Powder, | 10 | 19.3 | 19.3 |
| Phenobarbital | 9 | 14.6 | 14.6 |
| Thiotepa | 5 | 12.3 | 12.3 |
| Bleomycin Sulfate | 5 | 11.3 | 11.3 |
| Pemetrexed | 9 | 9.9 | 9.9 |
| Dasatinib | 15 | 9.5 | 9.6 |